Logo image of TLRY

TILRAY BRANDS INC (TLRY) Stock Fundamental Analysis

NASDAQ:TLRY - Nasdaq - US88688T1007 - Common Stock - Currency: USD

0.4871  -0.01 (-1.06%)

After market: 0.4899 +0 (+0.57%)

Fundamental Rating

2

Overall TLRY gets a fundamental rating of 2 out of 10. We evaluated TLRY against 198 industry peers in the Pharmaceuticals industry. TLRY has a bad profitability rating. Also its financial health evaluation is rather negative. TLRY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TLRY has reported negative net income.
TLRY had a negative operating cash flow in the past year.
TLRY had negative earnings in each of the past 5 years.
In the past 5 years TLRY reported 4 times negative operating cash flow.
TLRY Yearly Net Income VS EBIT VS OCF VS FCFTLRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B

1.2 Ratios

TLRY's Return On Assets of -27.79% is in line compared to the rest of the industry. TLRY outperforms 53.54% of its industry peers.
With a decent Return On Equity value of -34.64%, TLRY is doing good in the industry, outperforming 61.62% of the companies in the same industry.
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROIC N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
TLRY Yearly ROA, ROE, ROICTLRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

TLRY has a Gross Margin of 30.88%. This is comparable to the rest of the industry: TLRY outperforms 55.05% of its industry peers.
TLRY's Gross Margin has declined in the last couple of years.
TLRY does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
TLRY Yearly Profit, Operating, Gross MarginsTLRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

3

2. Health

2.1 Basic Checks

TLRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TLRY has more shares outstanding
The number of shares outstanding for TLRY has been increased compared to 5 years ago.
The debt/assets ratio for TLRY has been reduced compared to a year ago.
TLRY Yearly Shares OutstandingTLRY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
TLRY Yearly Total Debt VS Total AssetsTLRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of -0.74, we must say that TLRY is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -0.74, TLRY perfoms like the industry average, outperforming 53.54% of the companies in the same industry.
A Debt/Equity ratio of 0.11 indicates that TLRY is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.11, TLRY perfoms like the industry average, outperforming 50.51% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Altman-Z -0.74
ROIC/WACCN/A
WACC8.88%
TLRY Yearly LT Debt VS Equity VS FCFTLRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

2.3 Liquidity

A Current Ratio of 2.62 indicates that TLRY has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.62, TLRY is in line with its industry, outperforming 48.99% of the companies in the same industry.
TLRY has a Quick Ratio of 1.61. This is a normal value and indicates that TLRY is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.61, TLRY is not doing good in the industry: 61.62% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.61
TLRY Yearly Current Assets VS Current LiabilitesTLRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

5

3. Growth

3.1 Past

TLRY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.41%, which is quite impressive.
Looking at the last year, TLRY shows a quite strong growth in Revenue. The Revenue has grown by 11.23% in the last year.
TLRY shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 78.86% yearly.
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%

3.2 Future

The Earnings Per Share is expected to grow by 17.04% on average over the next years. This is quite good.
TLRY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.90% yearly.
EPS Next Y-206.98%
EPS Next 2Y20.45%
EPS Next 3Y21.44%
EPS Next 5Y17.04%
Revenue Next Year10.42%
Revenue Next 2Y7.89%
Revenue Next 3Y6.49%
Revenue Next 5Y5.9%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
TLRY Yearly Revenue VS EstimatesTLRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
TLRY Yearly EPS VS EstimatesTLRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -0.5 -1 -1.5 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TLRY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TLRY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLRY Price Earnings VS Forward Price EarningsTLRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TLRY is valued a bit cheaper than 79.29% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 21.03
TLRY Per share dataTLRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5 2 2.5

4.3 Compensation for Growth

TLRY's earnings are expected to grow with 21.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.45%
EPS Next 3Y21.44%

More info and screens

0

5. Dividend

5.1 Amount

TLRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TILRAY BRANDS INC

NASDAQ:TLRY (4/25/2025, 8:00:01 PM)

After market: 0.4899 +0 (+0.57%)

0.4871

-0.01 (-1.06%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)04-08 2025-04-08/bmo
Earnings (Next)07-28 2025-07-28/amc
Inst Owners11.8%
Inst Owner Change-0.01%
Ins Owners0.29%
Ins Owner Change0.02%
Market Cap490.27M
Analysts71.58
Price Target1.94 (298.28%)
Short Float %17.93%
Short Ratio5.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-140.2%
Min EPS beat(2)-145.1%
Max EPS beat(2)-135.29%
EPS beat(4)0
Avg EPS beat(4)-91.89%
Min EPS beat(4)-145.1%
Max EPS beat(4)-8.93%
EPS beat(8)1
Avg EPS beat(8)-85.68%
EPS beat(12)1
Avg EPS beat(12)-398.32%
EPS beat(16)4
Avg EPS beat(16)-256.75%
Revenue beat(2)0
Avg Revenue beat(2)-8.97%
Min Revenue beat(2)-13.28%
Max Revenue beat(2)-4.66%
Revenue beat(4)0
Avg Revenue beat(4)-7.31%
Min Revenue beat(4)-13.28%
Max Revenue beat(4)-0.75%
Revenue beat(8)1
Avg Revenue beat(8)-2.67%
Revenue beat(12)1
Avg Revenue beat(12)-3.36%
Revenue beat(16)1
Avg Revenue beat(16)-7.96%
PT rev (1m)0%
PT rev (3m)-14.72%
EPS NQ rev (1m)-150%
EPS NQ rev (3m)0%
EPS NY rev (1m)-413.11%
EPS NY rev (3m)-802.85%
Revenue NQ rev (1m)-8.94%
Revenue NQ rev (3m)-6.92%
Revenue NY rev (1m)-3.31%
Revenue NY rev (3m)-4.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.59
P/FCF N/A
P/OCF N/A
P/B 0.18
P/tB 0.84
EV/EBITDA 21.03
EPS(TTM)-0.28
EYN/A
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.05
OCFYN/A
SpS0.82
BVpS2.71
TBVpS0.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -27.79%
ROE -34.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.88%
FCFM N/A
ROA(3y)-16.09%
ROA(5y)-22.56%
ROE(3y)-20.59%
ROE(5y)-49.37%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y34.12%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.24
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF N/A
Debt/EBITDA 12.7
Cap/Depr 27.68%
Cap/Sales 4.39%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.61
Altman-Z -0.74
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)20.35%
Cap/Depr(5y)159.29%
Cap/Sales(3y)4.15%
Cap/Sales(5y)16.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y-206.98%
EPS Next 2Y20.45%
EPS Next 3Y21.44%
EPS Next 5Y17.04%
Revenue 1Y (TTM)11.23%
Revenue growth 3Y55.33%
Revenue growth 5Y78.86%
Sales Q2Q%-1.36%
Revenue Next Year10.42%
Revenue Next 2Y7.89%
Revenue Next 3Y6.49%
Revenue Next 5Y5.9%
EBIT growth 1Y-239.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year135.61%
EBIT Next 3Y37.38%
EBIT Next 5Y22.99%
FCF growth 1Y-24.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.12%
OCF growth 3YN/A
OCF growth 5YN/A